Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes - PubMed (original) (raw)
Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes
Nahla N Younis et al. Clin Sci (Lond). 2013 Mar.
Abstract
Glycation of apoB (apolipoprotein B) of LDL (low-density lipoprotein) increases its atherogenicity. Concentrations of both serum glyc-apoB (glycated apoB) and SD-LDL (small dense LDL) (syn LDL3; D=1.044-1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin- and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20±2 (means±S.D.) and 3.6±0.41 compared with 47±3 and 5.89±0.68 mg/dl in those not receiving statins (P<0.001 and <0.01, respectively). There was a dose-dependent increase in glycation on incubation of LDL subfractions with glucose, which was accompanied by an increase in LPO (lipid peroxide) and electrophoretic mobility and a decrease in free amino groups. SD-LDL was more susceptible to these changes than more buoyant LDL. Both SD-LDL and more buoyant LDL from statin-treated patients were less susceptible to glycation. There were fewer free amino groups on LDL subfractions from statin-treated patients, which may contribute to this resistance. In conclusion, greater susceptibility of SD-LDL to glycation is likely to contribute to the raised levels of circulating glyc-apoB in diabetes. Statins are associated with lower levels of both SD-LDL and glyc-apoB.
Similar articles
- Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes.
Younis NN, Soran H, Sharma R, Charlton-Menys V, Greenstein A, Elseweidy MM, Durrington PN. Younis NN, et al. Diab Vasc Dis Res. 2010 Oct;7(4):289-95. doi: 10.1177/1479164110383063. Epub 2010 Sep 27. Diab Vasc Dis Res. 2010. PMID: 20876207 - Susceptibility of LDL and its subfractions to glycation.
Soran H, Durrington PN. Soran H, et al. Curr Opin Lipidol. 2011 Aug;22(4):254-61. doi: 10.1097/MOL.0b013e328348a43f. Curr Opin Lipidol. 2011. PMID: 21734572 Review. - Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro.
Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN. Younis N, et al. Atherosclerosis. 2009 Jan;202(1):162-8. doi: 10.1016/j.atherosclerosis.2008.04.036. Epub 2008 Apr 26. Atherosclerosis. 2009. PMID: 18511055 - Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Vergès B. Duvillard L, et al. Eur J Clin Invest. 2000 Aug;30(8):685-94. Eur J Clin Invest. 2000. PMID: 10964160 - Statins and diabetes.
Carmena R, Betteridge DJ. Carmena R, et al. Semin Vasc Med. 2004 Nov;4(4):321-32. doi: 10.1055/s-2004-869589. Semin Vasc Med. 2004. PMID: 15861314 Review.
Cited by
- Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis.
Yi M, Toribio AJ, Salem YM, Alexander M, Ferrey A, Swentek L, Tantisattamo E, Ichii H. Yi M, et al. Int J Mol Sci. 2024 May 27;25(11):5831. doi: 10.3390/ijms25115831. Int J Mol Sci. 2024. PMID: 38892018 Free PMC article. Review. - Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosis.
Durrington P, Soran H. Durrington P, et al. Curr Opin Lipidol. 2024 Aug 1;35(4):171-178. doi: 10.1097/MOL.0000000000000936. Epub 2024 Jun 18. Curr Opin Lipidol. 2024. PMID: 38887979 Free PMC article. Review. - Opinion: Are mental health benefits of the ketogenic diet accompanied by an increased risk of cardiovascular disease?
Diamond DM, Mason P, Bikman BT. Diamond DM, et al. Front Nutr. 2024 May 1;11:1394610. doi: 10.3389/fnut.2024.1394610. eCollection 2024. Front Nutr. 2024. PMID: 38751739 Free PMC article. No abstract available. - Novel Glycomimetics Protect against Glycated Low-Density Lipoprotein-Induced Vascular Calcification In Vitro via Attenuation of the RAGE/ERK/CREB Pathway.
Sidgwick GP, Weston R, Mahmoud AM, Schiro A, Serracino-Inglott F, Tandel SM, Skeoch S, Bruce IN, Jones AM, Alexander MY, Wilkinson FL. Sidgwick GP, et al. Cells. 2024 Feb 8;13(4):312. doi: 10.3390/cells13040312. Cells. 2024. PMID: 38391925 Free PMC article. - Exploring the Interactions between Obesity and Diabetes: Implications for Understanding Metabolic Dysregulation in a Saudi Arabian Adult Population.
Ahmad MS, Minaee N, Serrano-Contreras JI, Kaluarachchi M, Shen EY, Boulange C, Ahmad S, Phetcharaburanin J, Holmes E, Wist J, Albaloshi AH, Alaama T, Damanhouri ZA, Lodge S. Ahmad MS, et al. J Proteome Res. 2024 Feb 2;23(2):809-821. doi: 10.1021/acs.jproteome.3c00717. Epub 2024 Jan 17. J Proteome Res. 2024. PMID: 38230637
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous